Future of Neuroscience Conference: 'New Genetics: The Future of Neurology'
Friday, May 1, 2009
Time: 9:00 a.m. –5:00 p.m.
This interactive day-long program focuses on the fascinating field of new genetics. The program will feature poster sessions, platform presentations, a series of case vignettes, a panel discussion, and several invited lecturers discussing new developments in the field. The presenters will combine high-level science with practical clinical application. Registration is required to attend this session, in addition to Annual Meeting registration fee.
Schedule
| 9:00–9:20 a.m. | Welcome and Introduction Jeffery M. Vance, MD, PhD, University of Miami |
| 9:20–9:55 a.m. | "History of Genetics" Kenneth H. Fischbeck, MD, FAAN, NINDS/NIH |
| 9:55–10:30 a.m. | "Genetics 101: Clinical" Thomas B. Bird, MD, FAAN, University of Washington |
| 10:30–11:05 a.m. | "Genetics 101: Technical/Toys" Stephen Zuchner, MD, University of Miami |
| 11:05–11:25 a.m. | Break and Posters |
| 11:25–11:55 a.m. | Abstract Presentations Novel Genetic Animal Models of Autism: Molecular Mechanisms
to Therapeutic Targets, |
| 11:55 AM–12:30 p.m. | "Epigenetics" Massimo Pandolfo, MD, University of Brussels |
| 12:30–1:30 p.m. | Luncheon and Posters |
| 1:30–2:05 p.m. | "Regulatory Systems" Derek Dykxhoorn, PhD, University of Miami |
| 2:05–2:35 p.m. | Abstract Presentations Reversal of myotonia and splicing defects by antisense oligomers
in a transgenic mouse model of myotonic dystrophy type 1 (DM1), |
| 2:35–3:10 p.m. | "Complex Genetics: Multiple Sclerosis" Jonathan Haines, MD, Vanderbilt University |
| 3:10–3:30 p.m. | Break |
| 3:30–4:05 p.m. | "Complex Genetics: Autism" Margaret A. Pericak-Vance, PhD, University of Miami |
| 4:05–4:40 p.m. | "Personalized Medicine" Jeffery M. Vance, MD, PhD, University of Miami |
| 4:40–5:00 p.m. | Questions and Answers |
Poster Presentations
Presentation Times: 11:00–11:20 a.m., 3:10–3:30 p.m.
SC02.001: Aβ42 trimer Gal 4-UAS gene vaccine with the gene gun to prevent Alzheimer's Disease, Roger N. Rosenberg, MD, Dallas, TX
SC02.002: Inhibition of Parkin or PINK1 Expression in SH-SY5Y Dopaminergic Cells Increases SH-SY5Y Sensitivity to Paraquat Induced Cytotoxicity, Loren Ornelas, BS, Salt Lake City, UT
SC02.003: Uptake and Outcome of Genetic Testing Among Participants of the DuchenneConnect Registry, Vanessa Rangel Miller, MS, Atlanta, GA
SC02.004: Family history of melanoma and Parkinson's disease risk, Xiang Gao, MD, PhD, Boston, MA
SC02.005: Genetic Studies on the NNIPPS Cohort: A New Tau Sub-haplotype in Progressive Supranuclear Palsy, Michael H. Parkinson, BSc(Hons), MSc, MBBS, London, United Kingdom
SC02.006: Genome Wide Association Studies in Parkinson Disease, Jeffery M. Vance, MD, PhD, Miami, FL
SC02.007: A human trial of HSV-mediated gene transfer for the treatment of chronic pain, David J. Fink, MD, Ann Arbor, MI
SC02.008: Candidate gene associations and epistatic interactions in cerebrovascular disease on MRI: The Atherosclerosis Risk In Communities (ARIC) study, Myriam Fornage, PhD, Houston, TX
SC02.009: Gene Expression Levels as Endophenotypes in Genome-Wide Association Studies to Identify Susceptibility Variants for Late-Onset Alzheimer's Disease, Nilufer Ertekin-Taner, MD, PhD, Jacksonville, FL
SC02.010: Meta-analysis of genome scans and replication identify CD6, ICSBP1, and TNFRSF1A as novel multiple sclerosis susceptibility loci, Philip De Jager, MD, PhD, Boston, MA
